Medannex is an award-winning Scottish biopharmaceutical company committed to unlocking the therapeutic potential of targeting annexin-A1.
Our goal is to create a first-in-class therapy to improve the lives of people impacted by cancers and autoimmune diseases.
Following a Series B fundraise, and supported by both the Scottish Investment Bank and Innovate UK, Medannex is collaborating with world-leading clinical experts to explore the huge therapeutic and commercial potential of our patent-protected immunomodulatory technology.
We are currently preparing to initiate a First-in-Human clinical oncology study with our lead antibody, MDX-124, later this year. Our non-clinical therapeutic development programme for autoimmune diseases continues in parallel.
Medannex won both ‘Investment of the Year’ and ‘Outstanding Skills Development’ at Scotland’s Life Sciences Annual Awards 2021.